{"id":11922,"date":"2022-09-06T06:20:02","date_gmt":"2022-09-06T06:20:02","guid":{"rendered":"https:\/\/msdconecta.co.cr\/es\/?post_type=therapeutic-area&p=11922"},"modified":"2026-07-02T12:35:36","modified_gmt":"2026-07-02T12:35:36","slug":"oncologia-wp-0641","status":"publish","type":"therapeutic-area","link":"https:\/\/msdconecta.co.cr\/es\/therapeutic-areas\/oncologia-wp-0641\/","title":{"rendered":"Descubra m\u00e1s sobre Oncolog\u00eda"},"content":{"rendered":"
\n
\n \n
\n \n
\n
\n \n
\n \n\n

CONOZCA LA INFORMACI\u00d3N M\u00c1S RELEVANTE DE LAS INDICACIONES APROBADAS EN CENTROAM\u00c9RICA Y CARIBE PARA KEYTRUDA.<\/strong><\/p><\/p>\n\n<\/div>\n\n <\/div>\n\n <\/div>\n\n<\/div>\n\n <\/div>\n\n <\/div>\n\n\n\n

Haga clic en las partes del cuerpo para acceder a la informaci\u00f3n de cada indicaci\u00f3n<\/strong><\/h4>\n\n\n
\n
\n \n
\n \n
\n
\n \n
\n \n
\n \n \"\"\n\n <\/a>\n <\/figure>\n\n\n
\n \n \"\"\n\n <\/a>\n <\/figure>\n\n\n
\n \n \"\"\n\n <\/a>\n <\/figure>\n\n\n
\n \n \"\"\n\n <\/a>\n <\/figure>\n\n\n
\n \n \"\"\n\n <\/a>\n <\/figure>\n\n\n
\n \n \"\"\n\n <\/a>\n <\/figure>\n\n<\/div>\n\n\n
\n \n
\n \n \"\"\n\n <\/a>\n <\/figure>\n\n\n
\n \n \"\"\n\n <\/a>\n <\/figure>\n\n\n
\n \n \"\"\n\n <\/a>\n <\/figure>\n\n\n
\n \n \"\"\n\n <\/a>\n <\/figure>\n\n\n
\n \n \"\"\n\n <\/a>\n <\/figure>\n\n\n
\n \n \"\"\n\n <\/a>\n <\/figure>\n\n<\/div>\n\n <\/div>\n\n <\/div>\n\n<\/div>\n\n <\/div>\n\n <\/div>\n\n\n
\n
\n \n
\n \n
\n
\n \n
\n \n
\n \n \"\"\n\n <\/a>\n <\/figure>\n\n\n
\n \n \"\"\n\n <\/a>\n <\/figure>\n\n\n
\n \n \"\"\n\n <\/a>\n <\/figure>\n\n\n
\n \n \"\"\n\n <\/a>\n <\/figure>\n\n\n
\n \n \"\"\n\n <\/a>\n <\/figure>\n\n\n
\n \n \"\"\n\n <\/a>\n <\/figure>\n\n<\/div>\n\n\n
\n \n
\n \n \"\"\n\n <\/a>\n <\/figure>\n\n\n
\n \n \"\"\n\n <\/a>\n <\/figure>\n\n\n
\n \n \"\"\n\n <\/a>\n <\/figure>\n\n\n
\n \n \"\"\n\n <\/a>\n <\/figure>\n\n\n
\n \n \"\"\n\n <\/a>\n <\/figure>\n\n\n
\n \n \"\"\n\n <\/a>\n <\/figure>\n\n<\/div>\n\n <\/div>\n\n <\/div>\n\n<\/div>\n\n <\/div>\n\n <\/div>\n\n\n\n

Un aliado en Centroam\u00e9rica y Caribe desde el 2016, que ahora cuenta con m\u00e1s de 25 indicaciones que brindan m\u00e1s ma\u00f1anas a m\u00e1s pacientes<\/h4>\n\n\n\n

C\u00c1NCER DE PULM\u00d3N NO MICROC\u00cdTICO (CPNM)<\/strong><\/p><\/p>\n\n\n\n

KN-189<\/strong><\/p>\n\n\n\n

L\u00ednea de tratamiento: <\/strong>Metast\u00e1sico- Primera l\u00ednea<\/p>\n\n\n\n

Biomarcador: <\/strong>No requiere<\/p>\n\n\n\n

Tratamiento: <\/strong>En combinaci\u00f3n con pemetrexed y quimioterapia basada en platino est\u00e1 indicado para el tratamiento de primera l\u00ednea del c\u00e1ncer de pulm\u00f3n no microc\u00edtico no escamoso metast\u00e1sico en adultos cuyos tumores no tengan mutaciones tumorales positivas de EGFR o ALK.<\/p>\n\n\n\n

\n\n\n\n

KN-407<\/strong><\/p>\n\n\n\n

L\u00ednea de tratamiento: <\/strong>Metast\u00e1sico- Primera l\u00ednea<\/p>\n\n\n\n

Biomarcador: <\/strong>No requiere<\/p>\n\n\n\n

Tratamiento: <\/strong>En combinaci\u00f3n con carboplatino y paclitaxel o nab-paclitaxel, est\u00e1 indicado para el tratamiento de primera l\u00ednea del c\u00e1ncer de pulm\u00f3n no microc\u00edtico escamoso metast\u00e1sico en adultos.<\/p>\n\n\n\n

\n\n\n\n

KN-024<\/strong><\/p>\n\n\n\n

L\u00ednea de tratamiento: <\/strong>Metast\u00e1sico- Primera l\u00ednea<\/p>\n\n\n\n

Biomarcador: <\/strong>PD-L1 \u226550% TPS<\/p>\n\n\n\n

Tratamiento: <\/strong>En monoterapia est\u00e1 indicado para el tratamiento de primera l\u00ednea del c\u00e1ncer de pulm\u00f3n no microc\u00edtico metast\u00e1sico en adultos cuyos tumores expresen PD-L1 con una proporci\u00f3n de marcador tumoral (TPS, por sus siglas en ingl\u00e9s) \u226550% sin mutaciones tumorales positivas de EGFR o ALK.<\/p>\n\n\n\n

\n\n\n\n

KN-010<\/strong><\/p>\n\n\n\n

L\u00ednea de tratamiento: <\/strong>Metast\u00e1sico- Segunda l\u00ednea<\/p>\n\n\n\n

Biomarcador: <\/strong>PD-L1 \u22651% TPS<\/p>\n\n\n\n

Tratamiento: <\/strong>En monoterapia est\u00e1 indicado para el tratamiento del c\u00e1ncer de pulm\u00f3n no microc\u00edtico localmente avanzado o metast\u00e1sico en adultos cuyos tumores expresen PD-L1 con una TPS \u22651% y que hayan recibido al menos un tratamiento de quimioterapia previo. Los pacientes con mutaciones tumorales positivas de EGFR o ALK deben haber recibido tambi\u00e9n terapia dirigida antes de recibir KEYTRUDA.<\/p>\n\n\n

\n
\n \n
\n \n\n

M\u00e1s informaci\u00f3n<\/a> <\/strong><\/p>\n\n<\/div>\n\n\n

\n \n\n

Volver arriba<\/a><\/span><\/strong><\/p>\n\n<\/div>\n\n <\/div>\n\n <\/div>\n\n\n\n

CARCINOMA DE C\u00c9LULAS ESCAMOSAS DE CABEZA Y CUELLO (CCECC)<\/strong><\/p><\/p>\n\n\n\n

KN-048<\/strong><\/p>\n\n\n\n

L\u00ednea de tratamiento: <\/strong>Metast\u00e1sico- Primera l\u00ednea<\/p>\n\n\n\n

Biomarcador: <\/strong>PD-L1 CPS \u2265 1<\/p>\n\n\n\n

Tratamiento: <\/strong>En monoterapia o en combinaci\u00f3n con quimioterapia basada en platino y 5-fluorouracilo (5-FU), est\u00e1 indicado para el tratamiento de primera l\u00ednea del carcinoma de c\u00e9lulas escamosas de cabeza y cuello metast\u00e1sico o recurrente irresecable en adultos cuyos tumores expresen PD-L1 con una CPS \u2265 1.<\/p>\n\n\n\n

\n\n\n\n

KN-040<\/strong><\/p>\n\n\n\n

L\u00ednea de tratamiento: <\/strong>Metast\u00e1sico- Segunda l\u00ednea<\/p>\n\n\n\n

Biomarcador: <\/strong>PD-L1 TPS \u2265 50%<\/p>\n\n\n\n

Tratamiento: <\/strong>En monoterapia est\u00e1 indicado para el tratamiento del carcinoma de c\u00e9lulas escamosas de cabeza y cuello recurrente o metast\u00e1sico en adultos cuyos tumores expresen PD-L1 con una TPS \u2265 50% y que progresen durante o despu\u00e9s de quimioterapia basada en platino.<\/p>\n\n\n

\n
\n \n
\n \n\n

M\u00e1s informaci\u00f3n<\/a> <\/strong><\/p>\n\n<\/div>\n\n\n

\n \n\n

Volver arriba<\/a><\/span><\/strong><\/p>\n\n<\/div>\n\n <\/div>\n\n <\/div>\n\n\n\n

CARCINOMA DE ESOF\u00c1GO<\/strong><\/p><\/p>\n\n\n\n

KN-590<\/strong><\/p>\n\n\n\n

L\u00ednea de tratamiento: <\/strong>Metast\u00e1sico- Primera l\u00ednea<\/p>\n\n\n\n

Biomarcador: <\/strong>PD-L1 <\/span>CPS \u2265 10<\/p>\n\n\n\n

Tratamiento: <\/strong>En combinaci\u00f3n con quimioterapia basada en platino y fluoropirimidina, est\u00e1 indicado para el tratamiento de primera l\u00ednea del carcinoma de es\u00f3fago o adenocarcinoma de la uni\u00f3n gastroesof\u00e1gica HER-2 negativo localmente avanzado irresecable o metast\u00e1sico, en adultos cuyos tumores expresen PD-L1 con una CPS \u2265 10.<\/p>\n\n\n

\n
\n \n
\n \n\n

M\u00e1s informaci\u00f3n<\/a> <\/strong><\/p>\n\n<\/div>\n\n\n

\n \n\n

Volver arriba<\/a><\/span><\/strong><\/p>\n\n<\/div>\n\n <\/div>\n\n <\/div>\n\n\n\n

C\u00c1NCER DE MAMA TRIPLE NEGATIVO<\/strong> <\/p><\/p>\n\n\n\n

KN-355<\/strong><\/p>\n\n\n\n

L\u00ednea de tratamiento: <\/strong>Metast\u00e1sico- Primera l\u00ednea<\/p>\n\n\n\n

Biomarcador: <\/strong>PD-L1 <\/span> CPS \u2265 10<\/span><\/p>\n\n\n\n

Tratamiento: <\/strong>En combinaci\u00f3n con quimioterapia, est\u00e1 indicado para el tratamiento del c\u00e1ncer de mama triple negativo localmente recurrente irresecable o metast\u00e1sico en adultos cuyos tumores expresen PD-L1 con una CPS \u2265 10 y que no hayan recibido quimioterapia previa para la enfermedad metast\u00e1sica.<\/p>\n\n\n\n

\n\n\n\n

KN-522<\/strong><\/p>\n\n\n\n

L\u00ednea de tratamiento: <\/strong>Adyuvante \u200b<\/p>\n\n\n\n

Biomarcador: <\/strong>No requiere<\/p>\n\n\n\n

Tratamiento: <\/strong>En combinaci\u00f3n con quimioterapia como tratamiento neoadyuvante y luego continuado en monoterapia como tratamiento adyuvante despu\u00e9s de la cirug\u00eda, est\u00e1 indicado para el tratamiento en adultos con c\u00e1ncer de mama triple negativo localmente avanzado o en estadio temprano con riesgo alto de recidiva.<\/p>\n\n\n

\n
\n \n
\n \n\n

M\u00e1s informaci\u00f3n <\/a><\/strong><\/p>\n\n<\/div>\n\n\n

\n \n\n

Volver arriba<\/a><\/span><\/strong><\/p>\n\n<\/div>\n\n <\/div>\n\n <\/div>\n\n\n\n

CARCINOMA DE C\u00c9LULAS RENALES (CCR)<\/strong><\/p><\/p>\n\n\n\n

KN-426<\/strong><\/p>\n\n\n\n

L\u00ednea de tratamiento: <\/strong>Metast\u00e1sico- Primera l\u00ednea<\/p>\n\n\n\n

Biomarcador: <\/strong>No requiere<\/p>\n\n\n\n

Tratamiento: <\/strong>En combinaci\u00f3n con axitinib, est\u00e1 indicado para el tratamiento de primera l\u00ednea del carcinoma de c\u00e9lulas renales avanzado en adultos.<\/p>\n\n\n\n

\n\n\n\n

KN-581<\/strong><\/p>\n\n\n\n

L\u00ednea de tratamiento: <\/strong>Metast\u00e1sico- Primera l\u00ednea<\/p>\n\n\n\n

Biomarcador: <\/strong>No requiere<\/p>\n\n\n\n

Tratamiento: <\/strong>En combinaci\u00f3n con lenvatinib, est\u00e1 indicado para el tratamiento de primera l\u00ednea del carcinoma de c\u00e9lulas renales avanzado en adultos.<\/p>\n\n\n\n

\n\n\n\n

KN-564<\/strong><\/p>\n\n\n\n

L\u00ednea de tratamiento:<\/strong> Adyuvante \u200b<\/p>\n\n\n\n

Biomarcador: <\/strong>No requiere<\/p>\n\n\n\n

Tratamiento: <\/strong>En monoterapia est\u00e1 indicado para el tratamiento adyuvante en adultos con carcinoma de c\u00e9lulas renales con aumento del riesgo de recidiva despu\u00e9s de nefrectom\u00eda, o despu\u00e9s de nefrectom\u00eda y resecci\u00f3n de las lesiones metast\u00e1sicas.<\/p>\n\n\n

\n
\n \n
\n \n\n

M\u00e1s informaci\u00f3n <\/a><\/strong><\/p>\n\n<\/div>\n\n\n

\n \n\n

Volver arriba<\/a><\/span><\/strong><\/p>\n\n<\/div>\n\n <\/div>\n\n <\/div>\n\n\n\n

C\u00c1NCER COLORRECTAL<\/strong><\/strong><\/p><\/p>\n\n\n\n

KN-177<\/strong><\/p>\n\n\n\n

L\u00ednea de tratamiento: <\/strong>Metast\u00e1sico- Primera l\u00ednea<\/p>\n\n\n\n

Biomarcador: <\/strong>dMMR\/MSI-H<\/p>\n\n\n\n

Tratamiento: <\/strong>En monoterapia est\u00e1 indicado en adultos con c\u00e1ncer colorrectal con MSI-H o dMMR en los siguientes contextos:
-Tratamiento de primera l\u00ednea del c\u00e1ncer colorrectal metast\u00e1sico.<\/p>\n\n\n\n

\n\n\n\n

KN-164<\/strong><\/p>\n\n\n\n

L\u00ednea de tratamiento: <\/strong>Metast\u00e1sico- Segunda l\u00ednea<\/p>\n\n\n\n

Biomarcador: <\/strong>dMMR\/MSI-H<\/p>\n\n\n\n

Tratamiento: <\/strong>En monoterapia est\u00e1 indicado en adultos con c\u00e1ncer colorrectal con MSI-H o dMMR en los siguientes contextos:
-Tratamiento del c\u00e1ncer colorrectal irresecable o metast\u00e1sico despu\u00e9s de quimioterapia de combinaci\u00f3n previa basada en fluoropirimidina.<\/p>\n\n\n

\n
\n \n
\n \n\n

M\u00e1s informaci\u00f3n <\/a><\/strong><\/p>\n\n<\/div>\n\n\n

\n \n\n

Volver arriba<\/a><\/span><\/strong><\/p>\n\n<\/div>\n\n <\/div>\n\n <\/div>\n\n\n\n

C\u00c1NCER UROTELIAL<\/strong><\/p><\/p>\n\n\n\n

KN-052<\/strong><\/p>\n\n\n\n

L\u00ednea de tratamiento: <\/strong>Metast\u00e1sico- Primera l\u00ednea<\/p>\n\n\n\n

Biomarcador: <\/strong>PD-L1 (CPS) \u2265 10 para cisplatino\/carboplatino inelegibles<\/p>\n\n\n\n

Tratamiento: <\/strong>En monoterapia est\u00e1 indicado para el tratamiento del carcinoma urotelial localmente avanzado o metast\u00e1sico en adultos que no son candidatos a quimioterapia basada en cisplatino y cuyos tumores expresen PD-L1 con una puntuaci\u00f3n positiva combinada (CPS, por sus siglas en ingl\u00e9s) \u2265 10.<\/p>\n\n\n\n

\n\n\n\n

KN-045<\/strong><\/p>\n\n\n\n

L\u00ednea de tratamiento: <\/strong>Metast\u00e1sico- Segunda l\u00ednea<\/p>\n\n\n\n

Biomarcador: <\/strong>No requiere<\/p>\n\n\n\n

Tratamiento: <\/strong>En monoterapia est\u00e1 indicado para el tratamiento del carcinoma urotelial localmente avanzado o metast\u00e1sico en adultos que hayan recibido quimioterapia previa basada en platino.<\/p>\n\n\n

\n
\n \n
\n \n\n

M\u00e1s informaci\u00f3n <\/strong><\/p>\n\n<\/div>\n\n\n

\n \n\n

Volver arriba<\/a><\/span><\/strong><\/p>\n\n<\/div>\n\n <\/div>\n\n <\/div>\n\n\n\n

C\u00c1NCER CERVICAL<\/strong><\/p><\/p>\n\n\n\n

KN-826<\/strong><\/p>\n\n\n\n

L\u00ednea de tratamiento: <\/strong>Persistente, recurrente y metast\u00e1sico\u200b<\/p>\n\n\n\n

Biomarcador: <\/strong>PD-L1 CPS\u22651<\/span><\/p>\n\n\n\n

Tratamiento: <\/strong>En combinaci\u00f3n con quimioterapia con o sin bevacizumab, est\u00e1 indicado para el tratamiento del c\u00e1ncer de cuello uterino persistente, recurrente o metast\u00e1sico en mujeres adultas cuyos tumores expresen PD-L1 con una CPS \u2265 1.<\/p>\n\n\n

\n
\n \n
\n \n\n

M\u00e1s in<\/a>formaci\u00f3n <\/a><\/strong><\/p>\n\n<\/div>\n\n\n

\n \n\n

Volver arriba<\/a><\/span><\/strong><\/p>\n\n<\/div>\n\n <\/div>\n\n <\/div>\n\n\n\n

LINFOMA DE HODGKIN CL\u00c1SICO (LHc)<\/strong><\/p><\/p>\n\n\n\n

KN-204<\/strong><\/p>\n\n\n\n

L\u00ednea de tratamiento: <\/strong>Reca\u00edda o refractario (2L+) \u200b<\/p>\n\n\n\n

Biomarcador: <\/strong>No requiere<\/p>\n\n\n\n

Tratamiento: <\/strong>En monoterapia est\u00e1 indicado para el tratamiento de pacientes adultos y pedi\u00e1tricos a partir de 3 a\u00f1os de edad con linfoma de Hodgkin cl\u00e1sico en reca\u00edda o refractario, que no han respondido a un trasplante aut\u00f3logo de progenitores hematopoy\u00e9ticos (TAPH) o despu\u00e9s de al menos dos tratamientos previos cuando el TAPH no es una opci\u00f3n de tratamiento.<\/p>\n\n\n

\n
\n \n
\n \n\n

M\u00e1s informaci\u00f3n<\/a> <\/strong><\/p>\n\n<\/div>\n\n\n

\n \n\n

Volver arriba<\/a><\/span><\/strong><\/p>\n\n<\/div>\n\n <\/div>\n\n <\/div>\n\n\n\n

MELANOMA<\/strong><\/p><\/p>\n\n\n\n

KN-006<\/strong><\/p>\n\n\n\n

L\u00ednea de tratamiento: <\/strong>Metast\u00e1sico- Primera l\u00ednea\u200b<\/p>\n\n\n\n

Biomarcador: <\/strong>No requiere<\/p>\n\n\n\n

Tratamiento: <\/strong>En monoterapia est\u00e1 indicado para el tratamiento en adultos y adolescentes a partir de 12 a\u00f1os de edad con melanoma avanzado (irresecable o metast\u00e1sico).<\/p>\n\n\n\n

\n\n\n\n

KN-054<\/strong><\/p>\n\n\n\n

L\u00ednea de tratamiento: <\/strong>Adyuvante<\/p>\n\n\n\n

Biomarcador: <\/strong>No requiere<\/p>\n\n\n\n

Tratamiento: <\/strong>En monoterapia est\u00e1 indicado para el tratamiento adyuvante en adultos y adolescentes a partir de 12 a\u00f1os de edad con melanoma en estadio IIB, IIC o III y que hayan sido sometidos a resecci\u00f3n completa.<\/p>\n\n\n

\n
\n \n
\n \n\n

M\u00e1s informaci\u00f3n <\/a><\/strong><\/p>\n\n<\/div>\n\n\n

\n \n\n

Volver arriba<\/a><\/span><\/strong><\/p>\n\n<\/div>\n\n <\/div>\n\n <\/div>\n\n\n\n

C\u00c1NCER G\u00c1STRICO<\/strong><\/p><\/p>\n\n\n\n

KN-811<\/strong><\/p>\n\n\n\n

L\u00ednea de tratamiento: <\/strong>Primera l\u00ednea en combinaci\u00f3n<\/p>\n\n\n\n

Biomarcador: <\/strong>PD-L1 con una CPS \u2265 1, HER-2 positivo<\/p>\n\n\n\n

Tratamiento: <\/strong>KEYTRUDA, en combinaci\u00f3n con trastuzumab, y quimioterapia basada en fluoropirimidona y platino, est\u00e1 indicado para el tratamiento de primera l\u00ednea del adenocarcinoma g\u00e1strico o de la uni\u00f3n gastroesof\u00e1gica HER-2 positivo localmente avanzado irresecable o metast\u00e1sico en adultos cuyos tumores expresen PD-L1 con una CPS \u2265 1.<\/p>\n\n\n\n

\n\n\n\n

KN-859<\/strong><\/p>\n\n\n\n

L\u00ednea de tratamiento: <\/strong>Primera l\u00ednea en combinaci\u00f3n<\/p>\n\n\n\n

Biomarcador: <\/strong>PD-L1 con una CPS \u2265 1, HER-2 negativo \u200b<\/p>\n\n\n\n

Tratamiento: <\/strong>KEYTRUDA, en combinaci\u00f3n con quimioterapia basada en fluoropirimidina y platino, est\u00e1 indicado para el tratamiento de primera l\u00ednea del adenocarcinoma g\u00e1strico o de la uni\u00f3n gastroesof\u00e1gica HER-2 negativo localmente avanzado irresecable o metast\u00e1sico en adultos cuyos tumores expresen PD-L1 con una CPS \u2265 1.<\/p>\n\n\n

\n
\n \n
\n \n\n

M\u00e1s informaci\u00f3n <\/a><\/strong><\/p>\n\n<\/div>\n\n\n

\n \n\n

Volver arriba<\/a><\/span><\/strong><\/p>\n\n<\/div>\n\n <\/div>\n\n <\/div>\n\n\n\n

C\u00c1NCER ENDOMETRIO<\/strong><\/strong><\/p><\/p>\n\n\n\n

KN-775<\/strong><\/p>\n\n\n\n

L\u00ednea de tratamiento: <\/strong>Segunda l\u00ednea en combinaci\u00f3n con lenvatinib<\/p>\n\n\n\n

Biomarcador: <\/strong>No se requiere (PD-L1 \/ MSI or MMR)<\/p>\n\n\n\n

Tratamiento: <\/strong>En combinaci\u00f3n con lenvatinib, est\u00e1 indicado para el tratamiento del c\u00e1ncer de endometrio avanzado o recurrente en mujeres adultas con progresi\u00f3n de la enfermedad durante o despu\u00e9s de un tratamiento previo basado en platino, en cualquier contexto, y que no son candidatas a cirug\u00eda curativa o radioterapia.\u200b<\/p>\n\n\n\n

\n\n\n\n

KN-158<\/strong><\/p>\n\n\n\n

L\u00ednea de tratamiento: <\/strong>Segunda l\u00ednea en Monoterapia\u200b\u200b<\/p>\n\n\n\n

Biomarcador: <\/strong>No se requiere PD-L1. (Si se requiere testeo de positivo de MSI-H o dMMR)\u200b<\/p>\n\n\n\n

Tratamiento: <\/strong>En monoterapia est\u00e1 indicado para el tratamiento de los siguientes tumores con MSI-H o dMMR en adultos con: C\u00e1ncer de endometrio avanzado o recurrente que ha progresado durante o despu\u00e9s de un tratamiento previo basado en platino, en cualquier contexto, y que no son candidatas a cirug\u00eda curativa o radioterapia.\u200b<\/p>\n\n\n

\n
\n \n
\n \n\n

M\u00e1s informaci\u00f3n <\/a><\/strong><\/p>\n\n<\/div>\n\n\n

\n \n\n

Volver arriba<\/a><\/span><\/strong><\/p>\n\n<\/div>\n\n <\/div>\n\n <\/div>\n\n\n

\n
\n \n
\n
\n
\n \n \n \n \n\n \n \n <\/use>\n<\/svg>\n <\/span>\n <\/span>\n

\n \n \n Informaci\u00f3n para Prescribir completa – KEYTRUDA\u00ae <\/a>\n <\/h2>\n\n <\/header>\n\n \n
\n \n \n <\/div>\n <\/section>\n
\n \n \n <\/div>\n<\/article>\n<\/div>\n\n
\n
\n
\n \n \n \n \n\n \n \n <\/use>\n<\/svg>\n <\/span>\n <\/span>\n

\n \n \n Informaci\u00f3n Seleccionada de Seguridad \ncompleta – KEYTRUDA\u00ae <\/a>\n <\/h2>\n\n <\/header>\n\n \n
\n \n \n <\/div>\n <\/section>\n
\n \n \n <\/div>\n<\/article>\n<\/div>\n <\/div>\n\n <\/div>\n\n\n
\n \n Acceder o inscribirme a Oncologia- Keytruda para ver m\u00e1s informaci\u00f3n<\/span>\n <\/a><\/div>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Haga clic en las partes del cuerpo para acceder a la informaci\u00f3n de cada indicaci\u00f3n Un aliado en Centroam\u00e9rica y […]<\/p>\n","protected":false},"author":1334,"featured_media":0,"parent":0,"menu_order":5,"template":"","meta":{"_mhh_mcn_text_direction":"","_mhh_mcn_language":"","_mhh_mcn_left_sidebar_settings":{"entityId":0},"_mhh_mcn_sidebar_settings":{"entityId":0},"mhh_mcn_side_navigation_style":{"fontSize":{"l":"","m":"","s":""},"lineHeight":{"l":1.5,"m":1.5,"s":1.5},"itemColor":"","hoverItemColor":"","currentItemColor":"","borderItemColor":"","backgroundItemHoverColor":"","themeColor":""},"_mhh_mcn_child_page_navigation":{"isActive":true,"isSticky":true},"hide_header":false,"show_top_bar":false,"hide_footer":false,"full_width_layout":false,"therapeutic_area_resource":[],"related_products":"","job_code":"","banner":null,"icon":null,"primary_tag":0,"editor_notices":[],"mconnectHideShareThis":false,"footnotes":"","mconnectIsArchiveTemplate":false,"mconnectArchiveFiltersDisabled":false,"mconnectArchiveLockAllPresetFilters":false,"mconnectArchiveHidePageSubmenu":false,"mconnectArchiveShowParentPageOnly":false,"mconnectArchiveDefaultOrder":"DESC","mconnectArchiveDefaultOrderBy":"date","mconnectArchivePostsPerPage":12,"mconnectArchivePostTypes":[],"mconnectArchiveAllowFilterBy":["category","tx-content-type","tx-product","tx-pathology","tx-active-ingredient","tx-therapeutic-area"],"mconnectArchiveTaxonomyOrder":[],"mconnectArchiveFilterSorting":["is_keyword"],"mconnectArchiveContentItemStyle":{"showExcerpt":true,"showImage":true,"showIcon":false,"showPrimaryTag":true,"showBorder":false,"showDates":false,"showCta":true,"isCard":false,"hasBackground":false,"showMetadata":true},"mconnectArchiveLayout":{"type":"list","hasFeatured":false},"mconnectDynamicTaxonomyEntities":[],"mconnectArchiveTerms_category":[],"mconnectArchiveAllowTerms_category":[],"mconnectArchiveTerms_tx-content-type":[],"mconnectArchiveAllowTerms_tx-content-type":[],"mconnectArchiveTerms_tx-product":[],"mconnectArchiveAllowTerms_tx-product":[],"mconnectArchiveTerms_tx-pathology":[],"mconnectArchiveAllowTerms_tx-pathology":[],"mconnectArchiveTerms_tx-active-ingredient":[],"mconnectArchiveAllowTerms_tx-active-ingredient":[],"mconnectArchiveTerms_tx-therapeutic-area":[],"mconnectArchiveAllowTerms_tx-therapeutic-area":[],"mconnectArchiveAllowTerms_dynamic-taxonomy":[],"mconnectArchiveLegacyDefaultTermsApplied":false,"mconnectContentUpdatesPerPage":10,"mconnectContentUpdatesViewMoreUrl":"","mconnectContentUpdatesTerms_tx-content-type":[],"mconnectContentUpdatesTerms_tx-product":[],"mconnectContentUpdatesTerms_tx-pathology":[],"mconnectContentUpdatesTerms_tx-active-ingredient":[],"mconnectContentUpdatesTerms_tx-therapeutic-area":[],"sidebar_toogle":0,"sidebar_toogle_notification_warning":true,"sidebar_toogle_notification_alert":true,"content_expiration_sidebar_date":"","content_expiration_sidebar_expired_post_status":"","content_expiration_sidebar_redirection":""},"categories":[],"tags":[],"ga4_page_audience":[1187],"ga4_page_birn_id":[],"ga4_page_branding":[382],"ga4_page_businessunit":[],"ga4_page_campaign":[],"ga4_page_content_purpose":[400],"ga4_page_customer_journey_stage":[447],"ga4_page_customer_specialty":[484],"ga4_page_experience":[],"ga4_page_indication":[],"ga4_page_material_intent":[],"ga4_page_product":[869],"ga4_page_region":[921],"ga4_page_therapeuticarea":[950],"therapeutic-area-group":[],"tx-therapeutic-area":[],"tx-product":[],"tx-pathology":[],"tx-content-type":[],"tx-active-ingredient":[],"mhh-area-of-interest":[],"access":[],"user_status":[],"user_role":[],"class_list":["post-11922","therapeutic-area","type-therapeutic-area","status-publish","hentry"],"yoast_head":"\nDescubra m\u00e1s sobre Oncolog\u00eda - MConnect Cenca Spanish<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/msdconecta.co.cr\/es\/therapeutic-areas\/oncologia-wp-0641\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Descubra m\u00e1s sobre Oncolog\u00eda - MConnect Cenca Spanish\" \/>\n<meta property=\"og:description\" content=\"Haga clic en las partes del cuerpo para acceder a la informaci\u00f3n de cada indicaci\u00f3n Un aliado en Centroam\u00e9rica y […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/msdconecta.co.cr\/es\/therapeutic-areas\/oncologia-wp-0641\/\" \/>\n<meta property=\"og:site_name\" content=\"MConnect Cenca Spanish\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-02T12:35:36+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/msdconecta.co.cr\/es\/therapeutic-areas\/oncologia-wp-0641\/\",\"url\":\"https:\/\/msdconecta.co.cr\/es\/therapeutic-areas\/oncologia-wp-0641\/\",\"name\":\"Descubra m\u00e1s sobre Oncolog\u00eda - MConnect Cenca Spanish\",\"isPartOf\":{\"@id\":\"https:\/\/msdconecta.co.cr\/es\/#website\"},\"datePublished\":\"2022-09-06T06:20:02+00:00\",\"dateModified\":\"2026-07-02T12:35:36+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/msdconecta.co.cr\/es\/therapeutic-areas\/oncologia-wp-0641\/#breadcrumb\"},\"inLanguage\":\"es-CO\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/msdconecta.co.cr\/es\/therapeutic-areas\/oncologia-wp-0641\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/msdconecta.co.cr\/es\/therapeutic-areas\/oncologia-wp-0641\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/msdconecta.co.cr\/es\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u00c1reas Terap\u00e9uticas\",\"item\":\"https:\/\/msdconecta.co.cr\/es\/therapeutic-areas\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Descubra m\u00e1s sobre Oncolog\u00eda\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/msdconecta.co.cr\/es\/#website\",\"url\":\"https:\/\/msdconecta.co.cr\/es\/\",\"name\":\"MConnect Cenca Spanish\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/msdconecta.co.cr\/es\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/msdconecta.co.cr\/es\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es-CO\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/msdconecta.co.cr\/es\/#organization\",\"name\":\"MConnect Cenca Spanish\",\"url\":\"https:\/\/msdconecta.co.cr\/es\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es-CO\",\"@id\":\"https:\/\/msdconecta.co.cr\/es\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/msdconecta.co.cr\/es\/wp-content\/uploads\/sites\/77\/2022\/07\/logo_tcm2359-1256911.png\",\"contentUrl\":\"https:\/\/msdconecta.co.cr\/es\/wp-content\/uploads\/sites\/77\/2022\/07\/logo_tcm2359-1256911.png\",\"width\":152,\"height\":48,\"caption\":\"MConnect Cenca Spanish\"},\"image\":{\"@id\":\"https:\/\/msdconecta.co.cr\/es\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Descubra m\u00e1s sobre Oncolog\u00eda - MConnect Cenca Spanish","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/msdconecta.co.cr\/es\/therapeutic-areas\/oncologia-wp-0641\/","og_locale":"es_ES","og_type":"article","og_title":"Descubra m\u00e1s sobre Oncolog\u00eda - MConnect Cenca Spanish","og_description":"Haga clic en las partes del cuerpo para acceder a la informaci\u00f3n de cada indicaci\u00f3n Un aliado en Centroam\u00e9rica y […]","og_url":"https:\/\/msdconecta.co.cr\/es\/therapeutic-areas\/oncologia-wp-0641\/","og_site_name":"MConnect Cenca Spanish","article_modified_time":"2026-07-02T12:35:36+00:00","twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/msdconecta.co.cr\/es\/therapeutic-areas\/oncologia-wp-0641\/","url":"https:\/\/msdconecta.co.cr\/es\/therapeutic-areas\/oncologia-wp-0641\/","name":"Descubra m\u00e1s sobre Oncolog\u00eda - MConnect Cenca Spanish","isPartOf":{"@id":"https:\/\/msdconecta.co.cr\/es\/#website"},"datePublished":"2022-09-06T06:20:02+00:00","dateModified":"2026-07-02T12:35:36+00:00","breadcrumb":{"@id":"https:\/\/msdconecta.co.cr\/es\/therapeutic-areas\/oncologia-wp-0641\/#breadcrumb"},"inLanguage":"es-CO","potentialAction":[{"@type":"ReadAction","target":["https:\/\/msdconecta.co.cr\/es\/therapeutic-areas\/oncologia-wp-0641\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/msdconecta.co.cr\/es\/therapeutic-areas\/oncologia-wp-0641\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/msdconecta.co.cr\/es\/"},{"@type":"ListItem","position":2,"name":"\u00c1reas Terap\u00e9uticas","item":"https:\/\/msdconecta.co.cr\/es\/therapeutic-areas\/"},{"@type":"ListItem","position":3,"name":"Descubra m\u00e1s sobre Oncolog\u00eda"}]},{"@type":"WebSite","@id":"https:\/\/msdconecta.co.cr\/es\/#website","url":"https:\/\/msdconecta.co.cr\/es\/","name":"MConnect Cenca Spanish","description":"","publisher":{"@id":"https:\/\/msdconecta.co.cr\/es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/msdconecta.co.cr\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es-CO"},{"@type":"Organization","@id":"https:\/\/msdconecta.co.cr\/es\/#organization","name":"MConnect Cenca Spanish","url":"https:\/\/msdconecta.co.cr\/es\/","logo":{"@type":"ImageObject","inLanguage":"es-CO","@id":"https:\/\/msdconecta.co.cr\/es\/#\/schema\/logo\/image\/","url":"https:\/\/msdconecta.co.cr\/es\/wp-content\/uploads\/sites\/77\/2022\/07\/logo_tcm2359-1256911.png","contentUrl":"https:\/\/msdconecta.co.cr\/es\/wp-content\/uploads\/sites\/77\/2022\/07\/logo_tcm2359-1256911.png","width":152,"height":48,"caption":"MConnect Cenca Spanish"},"image":{"@id":"https:\/\/msdconecta.co.cr\/es\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/therapeutic-area\/11922","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/therapeutic-area"}],"about":[{"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/types\/therapeutic-area"}],"author":[{"embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/users\/1334"}],"version-history":[{"count":63,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/therapeutic-area\/11922\/revisions"}],"predecessor-version":[{"id":96452,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/therapeutic-area\/11922\/revisions\/96452"}],"wp:attachment":[{"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/media?parent=11922"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/categories?post=11922"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/tags?post=11922"},{"taxonomy":"ga4_page_audience","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/ga4_page_audience?post=11922"},{"taxonomy":"ga4_page_birn_id","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/ga4_page_birn_id?post=11922"},{"taxonomy":"ga4_page_branding","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/ga4_page_branding?post=11922"},{"taxonomy":"ga4_page_businessunit","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/ga4_page_businessunit?post=11922"},{"taxonomy":"ga4_page_campaign","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/ga4_page_campaign?post=11922"},{"taxonomy":"ga4_page_content_purpose","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/ga4_page_content_purpose?post=11922"},{"taxonomy":"ga4_page_customer_journey_stage","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/ga4_page_customer_journey_stage?post=11922"},{"taxonomy":"ga4_page_customer_specialty","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/ga4_page_customer_specialty?post=11922"},{"taxonomy":"ga4_page_experience","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/ga4_page_experience?post=11922"},{"taxonomy":"ga4_page_indication","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/ga4_page_indication?post=11922"},{"taxonomy":"ga4_page_material_intent","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/ga4_page_material_intent?post=11922"},{"taxonomy":"ga4_page_product","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/ga4_page_product?post=11922"},{"taxonomy":"ga4_page_region","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/ga4_page_region?post=11922"},{"taxonomy":"ga4_page_therapeuticarea","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/ga4_page_therapeuticarea?post=11922"},{"taxonomy":"therapeutic-area-group","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/therapeutic-area-group?post=11922"},{"taxonomy":"tx-therapeutic-area","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/tx-therapeutic-area?post=11922"},{"taxonomy":"tx-product","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/tx-product?post=11922"},{"taxonomy":"tx-pathology","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/tx-pathology?post=11922"},{"taxonomy":"tx-content-type","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/tx-content-type?post=11922"},{"taxonomy":"tx-active-ingredient","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/tx-active-ingredient?post=11922"},{"taxonomy":"mhh-area-of-interest","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/mhh-area-of-interest?post=11922"},{"taxonomy":"access","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/access?post=11922"},{"taxonomy":"user_status","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/user_status?post=11922"},{"taxonomy":"user_role","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/user_role?post=11922"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}